Evolution of availability of curcumin inside poly-lactic-co-glycolic acid nanoparticles: Impact on antioxidant and antinitrosant properties

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 5355-5366

  Betbeder, Didier ^a,b,c   Lipka, Emmanuelle ^a,b,d   Howsam, Mike ^d   Carpentier, Rodolphe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c UNIVERSITÉ D'ARTOIS   (France)

^d UNIV LILLE   (France)

Author keywords

Antioxidant; Curcumin; Evolution; Maturation; PLGA nanoparticles

Indexed keywords

CURCUMIN; NANOPARTICLE; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; DETERGENT; GLYCOLIC ACID; GLYCOLIC ACID DERIVATIVE; LACTIC ACID; NITROGEN; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTINITROSANT DRUG ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG COATING; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; ENDOCYTOSIS; EPITHELIUM CELL; LIGHT DARK CYCLE; LIGHT EXPOSURE; NANOENCAPSULATION; TEMPERATURE SENSITIVITY; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; SOLUBILITY; TEMPERATURE; TUMOR CELL LINE;

ANTIOXIDANTS; CELL LINE, TUMOR; CURCUMIN; DETERGENTS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GLYCOLATES; HUMANS; LACTIC ACID; NANOPARTICLES; NITROGEN; POLYGLYCOLIC ACID; REACTIVE OXYGEN SPECIES; SOLUBILITY; TEMPERATURE;

EID: 84940054806     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S84760     Document Type: Article

References (63)

1. Tsang CK, Kelly TL, Sailor MJ, Li YY. Highly stable porous siliconcarbon composites as label-free optical biosensors. ACS Nano. 2012; 6(12):10546-10554.
2. Jovanovic SV, Boone CW, Steenken S, Trinoga M, Kaskey RB. How curcumin works preferentially with water soluble antioxidants. J Am Chem Soc. 2001;123(13):3064-3068.
3. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32(6):1053-1064.
4. Kelly MR, Xu J, Alexander KE, Loo G. Disparate effects of similar phenolic phytochemicals as inhibitors of oxidative damage to cellular DNA. Mutat Res. 2001;485(4):309-318.
5. Tanwar V, Sachdeva J, Kishore K, et al. Dose-dependent actions of curcumin in experimentally induced myocardial necrosis: a biochemical, histopathological, and electron microscopic evidence. Cell Biochem Func. 2010;28(1):74-82.
6. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch. 1985;180(5):402-404.
7. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15(12):1867-1876.
8. Liu KN, Lai CM, Lee YT, et al. Curcumin’s pre-incubation temperature affects its inhibitory potency toward amyloid fibrillation and fibril-induced cytotoxicity of lysozyme. Biochim Biophys Acta. 2012; 1820(11):1774-1786.
9. Niu Y, Ke D, Yang Q, et al. Temperature-dependent stability and DPPH scavenging activity of liposomal curcumin at pH 7.0. Food Chem. 2012; 135(3):1377-1382.
10. Tonnesen HH, Karlsen J, van Henegouwen GB. Studies on curcumin and curcuminoids. VIII. Photochemical stability of curcumin. Z Lebensm Unters Forsch. 1986;183(2):116-122.
11. Wang K, Qiu F. Curcuminoid metabolism and its contribution to the pharmacological effects. Curr Drug Metab. 2013;14(7):791-806.
12. Lirdprapamongkol K, Sakurai H, Kawasaki N, et al. Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells. Eur J Pharm Sci. 2005;25(1):57-65.
13. Maurya DK, Devasagayam TP. Antioxidant and prooxidant nature of hydroxycinnamic acid derivatives ferulic and caffeic acids. Food Chem Toxicol. 2010;48(12):3369-3373.
14. Tai A, Sawano T, Yazama F, Ito H. Evaluation of antioxidant activity of vanillin by using multiple antioxidant assays. Biochim Biophys Acta. 2011;1810(2):170-177.
15. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999; 27(4):486-494.
16. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007;330(1-2):155-163.
17. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 2007;60(2):171-177.
18. Tonnesen HH. Solubility, chemical and photochemical stability of cur cumin in surfactant solutions. Studies of curcumin and curcuminoids, XXVIII. Pharmazie. 2002;57(12):820-824.
19. Kumar V, Lewis SA, Mutalik S, Shenoy DB, Venkatesh, Udupa N. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmaco. 2002;46(2):209-217.
20. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104(6):1322-1331.
21. Sou K, Inenaga S, Takeoka S, Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm. 2008; 352(1-2):287-293.
22. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316.
23. Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm. 2007;67(2):361-369.
24. Bala I, Bhardwaj V, Hariharan S, Kharade SV, Roy N, Ravi Kumar MN. Sustained release nanoparticulate formulation containing antioxidant ellagic acid as potential prophylaxis system for oral administration. J Drug Target. 2006;14(1):27-34.
25. Le Broc-Ryckewaert D, Carpentier R, Lipka E, et al. Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. Int J Pharm. 2013;454(2):712-719.
26. Jain AK, Das M, Swarnakar NK, Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst. 2011;28(1):1-45.
27. Lu JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325-341.
28. Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S. Nanotechnologyapplied curcumin for different diseases therapy. Biomed Res Int. 2014; 2014:394264.
29. Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, Limtrakul P. Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmaco Sin. 2012;33(6):823-831.
30. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metabol. 2012;13(1):120-128.
31. Yallapu MM, Khan S, Maher DM, et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014; 35(30):8635-8648.
32. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PloS One. 2012;7(3):e32616.
33. Chang J, Paillard A, Passirani C, et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res. 2012;29(6):1495-1505.
34. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5): 387-422.
35. Lopez-Leon T, Carvalho EL, Seijo B, Ortega-Vinuesa JL, BastosGonzalez D. Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behavior. J Colloid Interface Sci. 2005;283(2):344-351.
36. Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24(1):67-75.
37. Kim S, Kim JC, Sul D, et al. Nanoparticle formulation for controlled release of capsaicin. J Nanosci Nanotechnol. 2011;11(5):4586-4591.
38. Mohammadi G, Nokhodchi A, Barzegar-Jalali M, et al. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces. 2011;88(1):39-44.
39. Chaudhuri A, Battaglia G, Golestanian R. The effect of interactions on the cellular uptake of nanoparticles. Phys Biol. 2011;8(4):046002.
40. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrinand caveolae-mediated endocytosis. Biochem J. 2004;377(Pt 1):159-169.
41. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. Size-dependent endocytosis of nanoparticles. Adv Mater. 2009;21:419-424.
42. Benmerah A, Lamaze C. Clathrin-coated pits: vive la difference? Traffic. 2007;8(8):970-982.
43. Jana NR. Design and development of quantum dots and other nanoparticles based cellular imaging probe. Phys Chem Chem Phys. 2011;13(2): 385-396.
44. Dombu CY, Kroubi M, Zibouche R, Matran R, Betbeder D. Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology. 2010;21(35):355102.
45. Sugiura H, Ichinose M. Oxidative and nitrative stress in bronchial asthma. Antioxid Redox Signal. 2008;10(4):785-797.
46. Gopinathan N, Yang B, Lowe JP, Edler KJ, Rigby SP. NMR cryoporometry characterisation studies of the relation between drug release profile and pore structural evolution of polymeric nanoparticles. Int J Pharm. 2014;469(1):146-158.
47. Grottkau BE, Cai X, Wang J, Yang X, Lin Y. Polymeric nanoparticles for a drug delivery system. Curr Drug Metab. 2013;14(8):840-846.
48. Rescignano N, Amelia M, Credi A, Kenny JM, Armentano I. Morphological and thermal behavior of porous biopolymeric nanoparticles. Eur Polym J. 2012;48(7):1152-1159.
49. Fielding AB, Willox AK, Okeke E, Royle SJ. Clathrin-mediated endocytosis is inhibited during mitosis. Proc Natl Acad Sci. 2012; 109(17):6572-6577.
50. Foerg C, Ziegler U, Fernandez-Carneado J, Giralt E, Merkle HP. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharm Res. 2007;24(4):628-642
51. Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposomecell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry. 1993;32(3):889-899.
52. Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011; 6(2):93-108.
53. Gonzalez-Reyes S, Guzman-Beltran S, Medina-Campos ON, PedrazaChaverri J. Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxid Med Cell Longev. 2013; 2013:801-418.
54. Barzegar A, Moosavi-Movahedi AA. Intracellular ROS protection efficiency and free radical-scavenging activity of curcumin. PloS One. 2011; 6(10):e26012.
55. Sreejayan, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm Parmacol. 1997;49(1):105-107.
56. Onoda M, Inano H. Effect of curcumin on the production of nitric oxide by cultured rat mammary gland. Nitric Oxide. 2000;4(5):505-515.
57. Johnston BD, DeMaster EG. Suppression of nitric oxide oxidation to nitrite by curcumin is due to the sequestration of the reaction intermediate nitrogen dioxide, not nitric oxide. Nitric Oxide. 2003;8(4):231-234.
58. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29(10):3867-3875.
59. Pawar YB, Shete G, Popat D, Bansal AK. Phase behavior and oral bioavailability of amorphous Curcumin. Eur J Pharm Sci. 2012;47(1): 56-64.
60. Al-Rohaimi AH. Comparative anti-inflammatory potential of crystalline and amorphous nano curcumin in topical drug delivery. J Oleo Sci. 2015;64(1):27-40.
61. Pfeiffer C, Rehbock C, Huhn D, et al. Interaction of colloidal nanoparticles with their local environment: the (ionic) nanoenvironment around nanoparticles is different from bulk and determines the physico-chemical properties of the nanoparticles. J R Soc, Interface. 2014;11(96):20130931.
62. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (plga) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3): 1377-1397.
63. Suwannateep N, Wanichwecharungruang S, Haag SF, et al. Encapsulated curcumin results in prolonged curcumin activity in vitro and radical scavenging activity ex vivo on skin after UVB-irradiation. Eur J Pharm Biopharm. 2012;82(3):485-490.